SieKCYMcgillTHealyGB. Subglottic hemangioma: ten years’ experience with the carbon dioxide laser. Ann Otol Rhinol Laryngol. 1994;103:167-172.
2.
O-LeeTJMessnerA. Subglottic hemangioma. Otolaryngol Clin North Am. 2008;41:903-911.
3.
BitarMAMoukarbelRVZalzalGH. Management of congenital subglottic hemangioma: trends and success over the past 17 years. Otolaryngol Head Neck Surg. 2005;132: 226-231.
4.
BielenbergDRBucanaCDSanchezRMullikenJBFolkmanJFidlerIJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol. 1999;14:401-408.
5.
D’AngeloGLeeHWeinerRI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem. 1997;67:353-366.
6.
VerhoeckxKCDoornbosRPWitkampRFvan der GreefJRodenburgRJ. Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. Int Immunopharmacol. 2006;6:1-7.
7.
StorchCHHoegerPH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269-274.
8.
SansVde la RoqueEDBergeJ. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124:e423-e431.
